Literature DB >> 31537090

Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression.

Cherise R Chin Fatt1, Manish K Jha1, Crystal M Cooper1, Gregory Fonzo1, Charles South1, Bruce Grannemann1, Thomas Carmody1, Tracy L Greer1, Benji Kurian1, Maurizio Fava1, Patrick J McGrath1, Phillip Adams1, Melvin McInnis1, Ramin V Parsey1, Myrna Weissman1, Mary L Phillips1, Amit Etkin1, Madhukar H Trivedi1.   

Abstract

OBJECTIVE: Major depressive disorder is associated with aberrant resting-state functional connectivity across multiple brain networks supporting emotion processing, executive function, and reward processing. The purpose of this study was to determine whether patterns of resting-state connectivity between brain regions predict differential outcome to antidepressant medication (sertraline) compared with placebo.
METHODS: Participants in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study underwent structural and resting-state functional MRI at baseline. Participants were then randomly assigned to receive either sertraline or placebo treatment for 8 weeks (N=279). A region of interest-based approach was utilized to compute functional connectivity between brain regions. Linear mixed-model intent-to-treat analyses were used to identify brain regions that moderated (i.e., differentially predicted) outcomes between the sertraline and placebo arms.
RESULTS: Prediction of response to sertraline involved several within- and between-network connectivity patterns. In general, higher connectivity within the default mode network predicted better outcomes specifically for sertraline, as did greater between-network connectivity of the default mode and executive control networks. In contrast, both placebo and sertraline outcomes were predicted (in opposite directions) by between-network hippocampal connectivity.
CONCLUSIONS: This study identified specific functional network-based moderators of treatment outcome involving brain networks known to be affected by major depression. Specifically, functional connectivity patterns of brain regions between and within networks appear to play an important role in identifying a favorable response for a drug treatment for major depressive disorder.

Entities:  

Keywords:  EMBARC; Functional Connectivity; Major Depressive Disorder; Moderators of Treatment Outcome

Mesh:

Substances:

Year:  2019        PMID: 31537090     DOI: 10.1176/appi.ajp.2019.18070870

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  19 in total

Review 1.  Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.

Authors:  Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk
Journal:  Drugs Aging       Date:  2021-04-29       Impact factor: 3.923

2.  Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial.

Authors:  Kevin P Nguyen; Cherise Chin Fatt; Alex Treacher; Cooper Mellema; Crystal Cooper; Manish K Jha; Benji Kurian; Maurizio Fava; Patrick J McGrath; Myrna Weissman; Mary L Phillips; Madhukar H Trivedi; Albert A Montillo
Journal:  Biol Psychiatry       Date:  2021-09-22       Impact factor: 13.382

3.  Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report.

Authors:  Gwen van der Wijk; Jacqueline K Harris; Stefanie Hassel; Andrew D Davis; Mojdeh Zamyadi; Stephen R Arnott; Roumen Milev; Raymond W Lam; Benicio N Frey; Geoffrey B Hall; Daniel J Müller; Susan Rotzinger; Sidney H Kennedy; Stephen C Strother; Glenda M MacQueen; Andrea B Protzner
Journal:  Cereb Cortex       Date:  2022-03-04       Impact factor: 4.861

4.  Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder.

Authors:  Marieke A G Martens; Nicola Filippini; Catherine J Harmer; Beata R Godlewska
Journal:  Psychopharmacology (Berl)       Date:  2021-09-03       Impact factor: 4.415

Review 5.  Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review.

Authors:  Ilya Demchenko; Vanessa K Tassone; Sidney H Kennedy; Katharine Dunlop; Venkat Bhat
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

6.  Individual-Specific Areal-Level Parcellations Improve Functional Connectivity Prediction of Behavior.

Authors:  Ru Kong; Qing Yang; Evan Gordon; Aihuiping Xue; Xiaoxuan Yan; Csaba Orban; Xi-Nian Zuo; Nathan Spreng; Tian Ge; Avram Holmes; Simon Eickhoff; B T Thomas Yeo
Journal:  Cereb Cortex       Date:  2021-08-26       Impact factor: 5.357

Review 7.  Research Review: Brain network connectivity and the heterogeneity of depression in adolescence - a precision mental health perspective.

Authors:  Rajpreet Chahal; Ian H Gotlib; Amanda E Guyer
Journal:  J Child Psychol Psychiatry       Date:  2020-05-26       Impact factor: 8.982

8.  Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges.

Authors:  Mary E Kelley; Ki Sueng Choi; Justin K Rajendra; W Edward Craighead; Jeffrey J Rakofsky; Boadie W Dunlop; Helen S Mayberg
Journal:  Biol Psychiatry       Date:  2021-02-26       Impact factor: 12.810

9.  A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants.

Authors:  Chadi G Abdallah; Kyung-Heup Ahn; Lynnette A Averill; Samaneh Nemati; Christopher L Averill; Samar Fouda; Mohini Ranganathan; Peter T Morgan; Deepak C D'Souza; Daniel H Mathalon; John H Krystal; Naomi R Driesen
Journal:  Neuropsychopharmacology       Date:  2020-09-23       Impact factor: 7.853

Review 10.  Functional neuroimaging biomarkers of resilience in major depressive disorder.

Authors:  Adina S Fischer; Kelsey E Hagan; Ian H Gotlib
Journal:  Curr Opin Psychiatry       Date:  2021-01       Impact factor: 4.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.